Production (Stage)
Travere Therapeutics, Inc.
TVTX
$15.84
$0.140.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 9.29% | 18.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.29% | 18.90% | |||
| Cost of Revenue | -20.20% | 21.23% | |||
| Gross Profit | 196.69% | 5.98% | |||
| SG&A Expenses | 4.80% | 5.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.24% | 12.78% | |||
| Operating Income | 28.08% | -5.90% | |||
| Income Before Tax | 31.74% | -10.04% | |||
| Income Tax Expenses | 154.17% | 14.29% | |||
| Earnings from Continuing Operations | 31.60% | -10.07% | |||
| Earnings from Discontinued Operations | -- | 106.78% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 31.59% | -9.95% | |||
| EBIT | 28.08% | -5.90% | |||
| EBITDA | 36.77% | -5.48% | |||
| EPS Basic | 35.66% | -2.91% | |||
| Normalized Basic EPS | 34.27% | -0.82% | |||
| EPS Diluted | 35.66% | -2.91% | |||
| Normalized Diluted EPS | 34.27% | -0.82% | |||
| Average Basic Shares Outstanding | 6.32% | 6.85% | |||
| Average Diluted Shares Outstanding | 6.32% | 6.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||